Laboratory Corporation of America Holdings Stock price
Equities
LH
US50540R4092
Healthcare Facilities & Services
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
197.66 USD | -1.69% | -5.10% | -16.00% |
Financials (USD)
Sales 2023 * | 12,213 M | Sales 2024 * | 12,481 M | Capitalization | 17 833 M |
---|---|---|---|---|---|
Net income 2023 * | 921 M | Net income 2024 * | 1,056 M | EV / Sales 2023 * | 1,76x |
Net Debt 2023 * | 3,703 M | Net Debt 2024 * | 3,470 M | EV / Sales 2024 * | 1,71x |
P/E ratio 2023 * | 19,8x | P/E ratio 2024 * | 16,9x | Employees | - |
Yield 2023 * | 1,45% | Yield 2024 * | 1,08% | Free-Float | 99.73% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.80% | ||
1 week | -4.47% | ||
Current month | -0.97% | ||
1 month | -2.62% | ||
3 months | -4.70% | ||
6 months | -13.62% | ||
Current year | -15.45% |
1 week
199.01
208.73

1 month
198.69
208.73

Current year
198.69
258.90

1 year
198.69
258.90

3 years
189.60
317.17

5 years
98.02
317.17

10 years
87.01
317.17

Managers | Title | Age | Since |
---|---|---|---|
Adam Schechter
CEO | Chief Executive Officer | 59 | 2019 |
Glenn Eisenberg
DFI | Director of Finance/CFO | 62 | 2014 |
Lance Berberian
CTO | Chief Tech/Sci/R&D Officer | 60 | 2014 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 2021 | |
Adam Schechter
CHM | Chairman | 59 | 2020 |
Kerrii Anderson
BRD | Director/Board Member | 65 | 2006 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.97% | 2 M$ | -7.95% | ||
1.95% | 8 M$ | -9.98% |
Date | Price | Change | Volume |
---|---|---|---|
23-10-02 | 197.56 | -1.74% | 190 502 |
23-09-29 | 201.05 | -1.09% | 1,090,832 |
23-09-28 | 203.26 | -0.78% | 809,340 |
23-09-27 | 204.85 | -0.25% | 757,100 |
23-09-26 | 205.36 | -1.47% | 938,743 |
Delayed Quote Nyse, October 02, 2023 at 09:41 am EDT
More quotes
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows:
- clinical laboratory services (63.9%): routine testing, patient diagnosis, disease monitoring and treatment, and other services;
- development and clinical trial services (36.1%): for pharmaceutical, biotechnology, medical device and diagnostic companies.
Net sales are distributed geographically as follows : North America (81.2%), Europe (12.7%) and other (6.1%).
Calendar
2023-10-25
- Q3 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
201.05USD
Average target price
245.85USD
Spread / Average Target
+22.28%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-15.45% | 17 833 M $ | |
-.--% | 252 M $ | |
-77.27% | 54 M $ | |
-12.86% | 284 M $ | |
+75.00% | 185 M $ | |
+109.07% | 168 M $ | |
+23.53% | 65 M $ | |
-15.79% | 277 M $ | |
+40.63% | 84 M $ | |
+22.21% | 419 M $ |